23 completed, 13 recruiting, 6 terminated, 5 active not recruiting. 52 Phase 2, 21 Phase 1.
Follow Brain Tumor: new trials by email Literature Review of Brain Tumor trials Research Report on Brain Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera - Brain Tumor | Phase 1 / Phase 2 | Recruiting | Stanford University | 12 | 2026-12-01 | 2026-09-29 |
| Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). BCB-276 - Diffuse Intrinsic Pontine Glioma, DIPG | Phase 2 | Recruiting | BrainChild Bio, Inc | 75 | 2026-09-04 | 2026-10-28 |
| Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain Memantine, Raloxifene - Brain Tumor | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 108 | 2026-07-06 | 2026-09-22 |
| A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Sitagliptin - Glioblastoma, Brain Tumor | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 48 | 2026-03-16 | 2026-08-06 |
| The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours 5-ALA (Gliolan) - Brain Tumor | Phase 2 | Not yet recruiting | University College, London | 80 | 2025-03-25 | 2025-03-27 |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss TNG456, abemaciclib - Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 191 | 2025-03-24 | 2026-10-21 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Brain Tumor, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-10-20 | 2024-11-05 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy Lithium, Placebo - Cognitive Impairment, Cognitive Decline | Phase 2 | Recruiting | Region Stockholm | 84 | 2024-02-16 | 2024-04-12 |
| SGM-101 in Colorectal Brain Metastases. SGM-101 - Rectal Neoplasms, Rectum Cancer | Phase 2 | Unknown | Leiden University Medical Center | 10 | 2024-01-01 | 2024-05-09 |
| 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations Zotiraciclib - Brain Tumor, Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 96 | 2023-05-16 | 2026-10-29 |
| ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids Nabiximols, Temozolomide, Nabiximols-matched placebo - Glioblastoma, Brain Tumor | Phase 2 | Active not recruiting | University of Birmingham | 122 | 2023-02-03 | 2026-10-16 |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Exablate, Doxorubicin - Brain Tumor | Phase 1 / Phase 2 | Active not recruiting | InSightec | 10 | 2023-01-04 | 2026-04-17 |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG Exablate, Doxorubicin - Brain Tumor | Phase 1 / Phase 2 | Active not recruiting | InSightec | 10 | 2023-01-04 | 2026-04-21 |
| Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study [18F]DPA714 - Brain Tumor, Medulloblastoma | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 22 | 2022-07-05 | 2026-10-19 |
| Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Stereotactic Radiation, AGuIX gadolinium-based nanoparticles, Placebo - Brain Cancer, Brain Metastases | Phase 2 | Recruiting | Brigham and Women's Hospital | 134 | 2021-09-15 | 2026-09-09 |
| LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma lerapolturev, pembrolizumab - Glioblastoma, Recurrent Glioblastoma | Phase 2 | Completed | Istari Oncology, Inc. | 25 | 2020-10-21 | 2025-06-05 |
| Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Lacosamide, Levetiracetam - Glioma, Glioma of Brain | Phase 2 | Terminated | Duke University | 4 | 2019-01-31 | 2023-04-13 |
| [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors [18F]FLT, [18F]Fluciclovine - Brain Tumor | Phase 1 / Phase 2 | Terminated | University of Utah | 10 | 2018-09-24 | 2024-12-27 |
Showing 20 of 52. Sign in to see all of them.
Brain Neoplasms (52) · Glioblastoma (23) · Glioma (14) · Astrocytoma (8) · Central Nervous System Neoplasms (8) · Neoplasms (6) · Oligodendroglioma (5) · Recurrence (5) · Ependymoma (4) · Gliosarcoma (4) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Medulloblastoma (3) · Meningioma (3) · Breast Neoplasms (2)
Central Nervous System Diseases (52) · Neoplasms by Site (52) · Nervous System Diseases (52) · Nervous System Neoplasms (52) · Brain Diseases (51) · Neoplasms (46) · Central Nervous System Neoplasms (44) · Neoplasms by Histologic Type (38) · Neoplasms, Germ Cell and Embryonal (37) · Neuroectodermal Tumors (36) · Neoplasms, Glandular and Epithelial (35) · Neoplasms, Nerve Tissue (35) · Neoplasms, Neuroepithelial (35) · Glioma (21) · Astrocytoma (19)
Temozolomide (8) · Bevacizumab (4) · Carboplatin (4) · Radiotherapy (4) · Cyclophosphamide (3) · Chemotherapy, Adjuvant (2) · Doxorubicin (2) · Etoposide (2) · Irinotecan (2) · Neoadjuvant Therapy (2) · Peripheral Blood Stem Cell Transplantation (2) · abemaciclib (2) · pembrolizumab (2) · 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (1) · Capecitabine (1)
National Cancer Institute (NCI) (6) · Children's Oncology Group (4) · Northwell Health (4) · Case Comprehensive Cancer Center (2) · Duke University (2) · InSightec (2) · Apollomics Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · BrainChild Bio, Inc (1) · Brigham and Women's Hospital (1) · Celtic Pharma Development Services (1) · Chinese PLA General Hospital (1) · Erasmus Medical Center (1) · Essen Biotech (1) · Istari Oncology, Inc. (1)
United States (40) · Canada (7) · Australia (5) · Netherlands (4) · Switzerland (4) · New Zealand (3) · Puerto Rico (3) · United Kingdom (3) · China (2) · France (2) · South Korea (2) · Hungary (1) · Italy (1) · Russia (1) · Singapore (1)
John Boockvar, MD (3) · David Peereboom, MD (2) · Stewart Goldman, MD (2) · Adam Crystal, MD, PhD (1) · Ahmed Idbaih, MD, PhD (1) · Andrew J Brenner, MD, PhD (1) · Annick Desjardins, M.D. (1) · Annick Desjardins, MD, FRCPC (1) · Asim Bag, MD (1) · Ayal Aizer, MD, MHS (1) · Bruce M Frankel, MD (1) · Carl Langberg, MD, PhD (1) · Clemens Dirven, MD PhD (1) · Cori Abikoff, MD (1) · David M. Peereboom, MD (1)
PMID 18623206, PMID 18989154, PMID 20381270, PMID 23817721, PMID 26645405, PMID 28057014, PMID 30118397, PMID 30717050, PMID 31545689, PMID 33312759, PMID 37786680, PMID 38796495, PMID 40040699, PMID 40241769, PMID 40842355
2014 (1), 2023 (1), P30CA043703 (1), R44CA261240 (1), U10CA081920 (1)